HappyDural

Company Overview

Snapshot

Founded in January 2021 by Shay Halamish and Dr. Zvi Isakson, HappyDural operates with 1–10 employees. The company secured its Seed funding round in February 2021 from investors including eHealth Ventures and Israel Innovation Authority.

Business overview

HappyDural develops an AI-based system for personalized sedative drug administration management. This technology aims to eliminate severe side effects from over-dosing and under-dosing during the entire injection period, significantly reducing the risk of life-threatening complications and pain. The solution integrates a sophisticated sensor array with a learning algorithm to provide automated, personalized, and immediate anesthesia monitoring, replacing manual procedures. HappyDural operates within the Digital Healthcare and Pharma & Medical Biotechnology sectors, specifically focusing on Drug Delivery and Patient Remote Monitoring, serving hospitals and healthcare providers.

Company Intelligence Q&A

What is HappyDural's primary focus?

HappyDural focuses on developing an AI-based system for personalized anesthesia management, aiming to prevent severe side effects from incorrect sedative drug administration.

When was HappyDural founded and by whom?

HappyDural was founded in January 2021 by Shay Halamish and Dr. Zvi Isakson.

What technology underpins HappyDural's solution?

HappyDural's solution is based on a sophisticated sensor array and a learning algorithm that enables automated monitoring for personalized and immediate anesthesia.

Which investors participated in HappyDural's Seed funding round?

In February 2021, HappyDural secured Seed funding from investors including eHealth Ventures and Israel Innovation Authority.

What is the current operational status of HappyDural?

HappyDural ceased to operate in September 2024.